Arlan Richardson
Showed rapamycin also extends lifespan when given later, and mapped its downstream biology
PhD, Oklahoma State University · Director, Oklahoma Nathan Shock Center of Excellence in the Basic Biology of Aging · Reynolds Chair in Aging Research, University of Oklahoma Health Sciences Center
Portrait: University of Oklahoma Health Sciences Center
Arlan Richardson has spent five decades studying the biology of aging, from the free-radical theory of aging to dietary restriction, moving through Illinois State University, the Barshop Institute at UT Health San Antonio (which he directed), and now the University of Oklahoma Health Sciences Center.
As part of the NIA's Interventions Testing Program collaboration, Richardson's group helped characterize how rapamycin changes the liver transcriptome and other downstream biology in treated mice, and has extended the question of mTOR's role in aging into models of Alzheimer's disease, showing that rapamycin can reduce amyloid-beta levels and reverse cognitive deficits in a mouse model.
The timeline below follows Richardson's contributions gathered in this Atlas.
Milestones in the Atlas
| Year | Evidence | Study |
|---|---|---|
| 2010 | A | Molecular interplay between mTOR, amyloid-beta, and Tau: effects on cognitive impairments CAC2010 Reviews the molecular interplay between mTOR, amyloid-beta and Tau, and its effects on cognitive impairment. |
| 2010 | A | Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease SPI2010 Shows rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. |
| 2014 | A | Mice fed rapamycin have an increase in lifespan associated with major changes in the liver transcriptome FOK2014 Shows mice fed rapamycin have an extended lifespan associated with major changes in the liver transcriptome. |